Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tandem mass spectrometry

This article was originally published in The Gray Sheet

Executive Summary

Pediatrix Medical Group's patent protections "could undermine the public health nature of newborn screening," Johns Hopkins University bioethicist Neil Holtzman, MD, warns in an editorial in the Nov. 19 issue of JAMA. "By charging royalties, Pediatrix could force nonprofit laboratories to either raise their prices or abandon tandem mass spectrometry," he states, noting that in Maryland the company offers screening at a lower price than the public program. Currently, Pediatrix reports positive test results to Maryland's health department, but in the future, the firm could refer infants to physicians within its own practice group, Holtzman cautions. In May, Pediatrix acquired privately held newborn screening lab Neo Gen Screening for $34 mil. (1"The Gray Sheet" May 19, 2003, p. 12)...

You may also be interested in...



Newborn Screening Trends Suggest Expanded Test Menus On Horizon

Pressure from patient organizations and parents are among factors driving an increase in the number of newborn screening tests included in mandatory state screening programs, according to Neo Gen Screening

Biogen Value-Based Contract Links Patient-Reported Outcomes To MS Drug Reimbursement

Biogen value-based contract with UPMC Health Plan ties payments to patient-reported outcomes for Tecfidera and Avonex. The company may seek something similar for Vumerity.

Outcomes-Based Contracts May Rely More On Patient-Reported Results

As interest in immune/inflammatory disease increases and savings achieved dip, payer focus on patient-reported outcomes for contracts reflects shift in focus, Avalere survey suggests.

UsernamePublicRestriction

Register

MT019380

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel